A large Italian study reveals a striking link between stopping GLP-1 therapy and higher rates of heart attack, stroke, or death, despite relatively small changes in conventional cardiovascular risk factors, raising questions about what really drives the increased risk.

Study: GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study. Image credit: Celso Pupo/Shutterstock.com

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have made a meteoric entry on the pharmaceutical stage with their ability to produce striking changes in body weight and markers of cardiometabolic risk. A recent study in The Lancet Regional Health – Europe links interruption of GLP-1RA treatment to approximately twice the incidence of a composite of heart attack, stroke, or death from any cause in people with type 2 diabetes (T2D) without previous major cardiovascular events.

High GLP-1RA discontinuation rates raise cardiovascular concerns

GLP-1RAs reduce cardiovascular events and mortality in people with T2D and in some subgroups with obesity. However, discontinuation rates range from 20% to 50% within the first year. This pattern is associated with weight regain and a rise in blood sugar, lipids, and blood pressure. Little is known about whether this translates into actual increases in mortality or cardiovascular events compared to continued treatment.

Only one large study of people with T2D has found that compared with patients discontinuing sulfonylureas, those stopping GLP-1RAs had a higher cardiovascular risk.

Researchers investigate cardiovascular outcomes after stopping GLP-1 therapy

The retrospective cohort study used data collected between 2004 and 2024 from 301 diabetes clinics across Italy. The authors examined only individuals with T2D who received at least one GLP-1RA prescription. Those who already had a history of a major cardiovascular event at the time of prescription were not eligible.

Treatment discontinuation was defined as not receiving a GLP-1RA prescription in two or more consecutive visits, while those who were still receiving GLP-1RAs at the last visit were defined as persistent users.

The primary endpoint was a composite of nonfatal myocardial infarction (MI), nonfatal stroke, or death from any cause, while on or off treatment. Death from any cause was also assessed separately as a secondary endpoint. Sensitivity analyses used an alternative definition of discontinuation, while additional analyses examined whether the association differed according to obesity status. In exploratory analyses, they compared trends in different risk factors between the two groups.

Stopping GLP-1 therapy linked to twice the adverse outcomes

Of the 80,302 GLP-1RA users, 31,687 were persistent users compared with 48,615 who discontinued treatment. The mean duration of GLP-1RA exposure was 2.97 years and 1.21 years among persistent and discontinued users, respectively.

Patients discontinuing GLP-1RAs were more likely to be women and on treatment with sulfonylureas, with other clinical features being similar. The final matched groups each consisted of 28,713 individuals.

During the observation period, 3,143 and 2,122 primary endpoint events occurred during treatment and after discontinuation, respectively. Discontinuation was associated with approximately twice the incidence of the primary outcome of nonfatal heart attack, nonfatal stroke, or death from any cause (3.94 vs 1.96 events per 100 person-years).

Mortality rates nearly fivefold higher after GLP-1RA discontinuation

Regarding the secondary endpoint, there were 788 and 1,242 deaths from any cause during treatment and after discontinuation, respectively. The corresponding incidence rates were 0.48 and 2.23 deaths per 100 person-years.

Similar results were obtained in the sensitivity and obesity-stratified analyses, though the association was more pronounced among individuals with obesity in the latter. Most measured risk factors at discontinuation were either similar to or improved compared to baseline.

GLP-1RA benefits may extend beyond conventional risk factors

GLP-1RAs have demonstrated substantial benefits for cardiovascular and renal health, besides their remarkable glucose- and weight-lowering effects. However, they have high discontinuation rates, often due to gastrointestinal adverse effects, perceptions of inadequate effects, high costs, and concerns about side effects.

Discontinuation is often followed by rapid weight regain. However, the current study found only modest weight regain and no deterioration in glycemic control after treatment cessation. The findings raise the possibility that GLP-1RAs provide cardiovascular benefits beyond their effects on conventional risk factors, although this remains speculative.

Given the high rate of gastrointestinal side effects, the authors suggest that more flexible dose-escalation regimens could improve tolerability and avoid discontinuation.

Unmeasured health factors complicate interpretation of mortality findings

The study included only individuals with T2D and without prior cardiovascular events, limiting its generalizability to GLP-1RA users with other indications. This study also did not include tirzepatide because it was introduced in Italy after the data collection phase.

The study is observational and cannot support causal inferences or rule out reverse causation, and it could not determine whether starting and then stopping GLP-1RA therapy carries a higher risk than never using these medications.

The authors note that socioeconomic data or the causes of drug discontinuation were not available, though both are relevant to cardiometabolic health.

The development of frailty or malignancies might have driven discontinuation, indicating possible reverse causation. The authors emphasize the large size of the mortality association compared with the cardiovascular benefits observed in earlier randomized trials. They conclude that treatment withdrawal alone is unlikely to explain this association and that other unmeasured factors, perhaps indicative of poorer underlying health, contributed to this association.

Cardiovascular and non-cardiovascular mortality could not be separately assessed in this setting, and there was inadequate information on heart failure hospitalizations across centers. Finally, as with all discontinuation studies, time-dependent confounding could not be fully accounted for.

GLP-1RA discontinuation emerges as a marker of increased cardiovascular risk

Compared with persistent users, individuals who discontinued GLP-1RA therapy had approximately twice the incidence of a composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or all-cause death, and an even higher relative incidence of all-cause mortality. The association may not be fully explained by changes in conventional cardiovascular risk factors, which were small.

These findings should be considered hypothesis-generating and require further examination in specifically designed prospective